Simcere Pharmaceutical Group (FRA:S2P) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S2P Simcere Pharmaceutical Group Ltd FRA:S2P
92 GF Score
Price €1.31
GF Value €1.19
Valuation Fairly Valued
View Full Analysis

What is Simcere Pharmaceutical Group Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:S2P
92GF Score
Simcere Pharmaceutical Group Ltd FRA:S2P
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.31 is trading 10.1% above its estimated GF Value™ of €1.19. GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.

Key valuation signals for FRA:S2P:

  • Cash Payments:
  • GF Value™: €1.19 vs. price of €1.31 (10.1% above fair value)
  • GF Score™: 92/100

No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
92GF Score

Get the complete analysis for FRA:S2P

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€1.19
GF Value